2 Brain-Computer Interface Stocks to Watch While Neuralink Stays Private
Neuralink, a private brain-computer interface (BCI) company, successfully helped a patient with ALS communicate. Investors cannot buy Neuralink, but two public companies, Quantum-Si (QSI) and Butterfly Network (BFLY), are connected to the BCI field. QSI makes research tools and saw a 7x volume spike, while BFLY supplies ultrasound chips to BCI developers like Merge Labs and Bridge Neurotech.
How this was made
The 30-second read
Why it matters
New licensing agreements for Butterfly Network provide fresh commercial validation, while Quantum‑Si's volume spike reflects speculative interest without solid fundamentals.
Market read
Both stocks could experience price moves driven by contract news (BFLY) and speculative volume activity (QSI).
What to watch
Regulatory clearance for BCI applications and competition from larger imaging firms could constrain upside.
Background
The article is a watchlist piece recommending two public stocks tied to the private brain‑computer‑interface sector.
Ticker impact
Quantum‑Si announced a 7x volume spike and a pending product launch, with $344k revenue and a delayed Proteus release, making it a high‑risk speculative play.
potential upside if the Proteus launch succeeds, but likely pressure from execution risk and cash burn.
Volume surge indicates interest, yet revenue is minimal and launch delayed, so price may swing sharply on any news.
Butterfly Network disclosed new agreements with Merge Labs and Bridge Neurotech to supply its ultrasound‑on‑chip technology for brain‑computer interface development.
likely upward pressure as the market prices in potential licensing revenue and expanded addressable market.
New multi‑year agreements represent fresh commercial traction for a small‑cap medical‑device firm.
Market effects
Highlights growing interest in brain‑computer interface technology, potentially boosting related med‑tech and research‑tool stocks.
U.S. small‑cap healthcare sector may see modest inflows as investors chase BCI exposure.
Limited to niche BCI and biotech investors; no broad macro impact.
Counterpoint
The contracts are early‑stage and may not translate into meaningful revenue; BFLY could face execution risk.
Key entities
- companyQuantum‑Si Inc.
Research‑tools provider with upcoming Proteus protein‑analysis platform.
- companyButterfly Network Inc.
Ultrasound‑on‑chip maker securing BCI developer contracts.
